Tumor dormancy of primary and secondary cancers

被引:60
作者
Udagava, Taturo [1 ,2 ,3 ]
机构
[1] Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA
[2] Childrens Hosp, Dept Surg, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Karp Family Res Labs, Boston, MA 02115 USA
关键词
dormancy; metastasis; latency; minimal residual disease; tumor stem cell;
D O I
10.1111/j.1600-0463.2008.01077.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Tumor doramncy is a phenomenon whereby cancer cells persist below the threshold of diagnostic detection for months to decades. This condition may arise due to either cell cycle arrrest or a dynamic equilibrium state in which cell proliferation is in balancef with cells undergoing apoptosis. Tumor dormancy isusually a reference to occult cancer cells that persist for an extended perios of time after treatment, but primary cancers can also exhibit extended growth plateaus below the limits of detection, For example, autopsies of individuals who died of trauma reveal that most individuals harbor microscopic primary cancers. Mechanisms that operate independently or succesively may restrict tumor expansion throughout tumor progression from incipiency to late-stage cancer. Proposed mechanisms include cell cycle withdrawal, immune surveillancfe, and blockes angiogenesis. The precise mechanisms underlying dormancy remain to be established, and relevant models will have an important impact on diagnostic and therapeutic stratergies for treating cancer. This review summarizes the phenomenon of tumor dormancy, experimental models, and potential mechanisms.
引用
收藏
页码:615 / 628
页数:14
相关论文
共 133 条
[1]   Heterogeneity of angiogenic activity in a human liposarcoma: A proposed mechanism for "no take" of human tumors in mice [J].
Achilles, EG ;
Fernandez, A ;
Allred, EN ;
Kisker, O ;
Udagawa, T ;
Beecken, WD ;
Flynn, E ;
Folkman, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1075-1081
[2]  
ADAMS JC, 1993, DEVELOPMENT, V117, P1183
[3]   Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth [J].
Aguirre-Ghiso, JA ;
Ossowski, L ;
Rosenbaum, SK .
CANCER RESEARCH, 2004, 64 (20) :7336-7345
[4]  
Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684
[5]   Selection of optimal adjuvant endocrine therapy for early-stage breast cancer [J].
Al-Hajj A. ;
O'Regan R. .
Current Treatment Options in Oncology, 2006, 7 (2) :153-165
[6]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[7]  
ALBELDA SM, 1993, LAB INVEST, V68, P4
[8]   Cancer in rodents: Does it tell us about cancer in humans? [J].
Anisimov, VN ;
Ukraintseva, SV ;
Yashin, AL .
NATURE REVIEWS CANCER, 2005, 5 (10) :807-819
[9]  
Aplin AE, 1999, J CELL SCI, V112, P695
[10]   Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways [J].
Arbiser, JL ;
Moses, MA ;
Fernandez, CA ;
Ghiso, N ;
Cao, YH ;
Klauber, N ;
Frank, D ;
Brownlee, M ;
Flynn, E ;
Parangi, S ;
Byers, HR ;
Folkman, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (03) :861-866